Juvenescence Limited: Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer
Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer.
Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the ?rst place. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors.
Dr. Piizzi has more than 15 years of experience in the global pharmaceutical and biotech industry. Most recently, she was the SVP of Small Molecules R&D and Head of Inflammation at a Flagship Pioneering startup, Cygnal Therapeutics, decoding the links between peripheral neurons and diseases (2019-2021). Previously, she held the position of Executive Di
Critical Reagent Portfolio Management – An End-to-End Solution, Upcoming Webinar Hosted by Xtalks
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Evgen Pharma PLC now has the financial runway to exploit its technology after transformative City fundraiser
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd
Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario– – Portage Biotech Inc. a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd., a company …
Portage may be entitled to up to USD $244 million in future milestone payments –
Toronto, Ontario–(Newsfile Corp. – March 4, 2021) – Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited (PPL), including subsidiaries Portage Glasgow Ltd. and EyGen L